1www › Citations

Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor.

Wiesmann C, Ultsch MH, Bass SH, de Vos AM
Nature 401 184-8 (1999)
Cited: 215 times
EuropePMC logo PMID: 10490030

Abstract

Nerve growth factor (NGF) is involved in a variety of processes involving signalling, such as cell differentiation and survival, growth cessation and apoptosis of neurons. These events are mediated by NGF as a result of binding to its two cell-surface receptors, TrkA and p75. TrkA is a receptor with tyrosine kinase activity that forms a high-affinity binding site for NGF. Of the five domains comprising its extracellular portion, the immunoglobulin-like domain proximal to the membrane (TrkA-d5 domain) is necessary and sufficient for NGF binding. Here we present the crystal structure of human NGF in complex with human TrkA-d5 at 2.2 A resolution. The ligand-receptor interface consists of two patches of similar size. One patch involves the central beta-sheet that forms the core of the homodimeric NGF molecule and the loops at the carboxy-terminal pole of TrkA-d5. The second patch comprises the amino-terminal residues of NGF, which adopt a helical conformation upon complex formation, packing against the 'ABED' sheet of TrkA-d5. The structure is consistent with results from mutagenesis experiments for all neurotrophins, and indicates that the first patch may constitute a conserved binding motif for all family members, whereas the second patch is specific for the interaction between NGF and TrkA.

Reviews - 1www mentioned but not cited (2)

  1. Structural Basis for LAR-RPTP-Mediated Synaptogenesis. Won SY, Kim HM. Mol Cells 41 622-630 (2018)
  2. Overview of protein structural and functional folds. Sun PD, Foster CE, Boyington JC. Curr Protoc Protein Sci Chapter 17 Unit 17.1 (2004)

Articles - 1www mentioned but not cited (35)

  1. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, Maruoka M, Mao W, Foster J, Kelley RF, Pan G, Gurney AL, de Vos AM, Starovasnik MA. EMBO J 20 5332-5341 (2001)
  2. Structural interactions of fibroblast growth factor receptor with its ligands. Stauber DJ, DiGabriele AD, Hendrickson WA. Proc Natl Acad Sci U S A 97 49-54 (2000)
  3. The nerve of ovulation-inducing factor in semen. Ratto MH, Leduc YA, Valderrama XP, van Straaten KE, Delbaere LT, Pierson RA, Adams GP. Proc Natl Acad Sci U S A 109 15042-15047 (2012)
  4. A new nerve growth factor-mimetic peptide active on neuropathic pain in rats. Colangelo AM, Bianco MR, Vitagliano L, Cavaliere C, Cirillo G, De Gioia L, Diana D, Colombo D, Redaelli C, Zaccaro L, Morelli G, Papa M, Sarmientos P, Alberghina L, Martegani E. J Neurosci 28 2698-2709 (2008)
  5. Molecular and structural insight into proNGF engagement of p75NTR and sortilin. Feng D, Kim T, Ozkan E, Light M, Torkin R, Teng KK, Hempstead BL, Garcia KC. J Mol Biol 396 967-984 (2010)
  6. Design of protein-binding proteins from the target structure alone. Cao L, Coventry B, Goreshnik I, Huang B, Sheffler W, Park JS, Jude KM, Marković I, Kadam RU, Verschueren KHG, Verstraete K, Walsh STR, Bennett N, Phal A, Yang A, Kozodoy L, DeWitt M, Picton L, Miller L, Strauch EM, DeBouver ND, Pires A, Bera AK, Halabiya S, Hammerson B, Yang W, Bernard S, Stewart L, Wilson IA, Ruohola-Baker H, Schlessinger J, Lee S, Savvides SN, Garcia KC, Baker D. Nature 605 551-560 (2022)
  7. Quantitative prediction of protein-protein binding affinity with a potential of mean force considering volume correction. Su Y, Zhou A, Xia X, Li W, Sun Z. Protein Sci 18 2550-2558 (2009)
  8. Fitting multimeric protein complexes into electron microscopy maps using 3D Zernike descriptors. Esquivel-Rodríguez J, Kihara D. J Phys Chem B 116 6854-6861 (2012)
  9. Low molecular weight, non-peptidic agonists of TrkA receptor with NGF-mimetic activity. Scarpi D, Cirelli D, Matrone C, Castronovo G, Rosini P, Occhiato EG, Romano F, Bartali L, Clemente AM, Bottegoni G, Cavalli A, De Chiara G, Bonini P, Calissano P, Palamara AT, Garaci E, Torcia MG, Guarna A, Cozzolino F. Cell Death Dis 3 e339 (2012)
  10. Designing coarse grained-and atom based-potentials for protein-protein docking. Tobi D. BMC Struct Biol 10 40 (2010)
  11. Functional Characterization of Human ProNGF and NGF Mutants: Identification of NGF P61SR100E as a "Painless" Lead Investigational Candidate for Therapeutic Applications. Malerba F, Paoletti F, Bruni Ercole B, Materazzi S, Nassini R, Coppi E, Patacchini R, Capsoni S, Lamba D, Cattaneo A. PLoS One 10 e0136425 (2015)
  12. The Inorganic Side of NGF: Copper(II) and Zinc(II) Affect the NGF Mimicking Signaling of the N-Terminus Peptides Encompassing the Recognition Domain of TrkA Receptor. Pandini G, Satriano C, Pietropaolo A, Gianì F, Travaglia A, La Mendola D, Nicoletti VG, Rizzarelli E. Front Neurosci 10 569 (2016)
  13. The myelin oligodendrocyte glycoprotein directly binds nerve growth factor to modulate central axon circuitry. von Büdingen HC, Mei F, Greenfield A, Jahn S, Shen YA, Reid HH, McKemy DD, Chan JR. J Cell Biol 210 891-898 (2015)
  14. Molecular dynamics simulations of the NGF-TrkA domain 5 complex and comparison with biological data. Settanni G, Cattaneo A, Carloni P. Biophys J 84 2282-2292 (2003)
  15. The Copper(II)-Assisted Connection between NGF and BDNF by Means of Nerve Growth Factor-Mimicking Short Peptides. Naletova I, Satriano C, Pietropaolo A, Gianì F, Pandini G, Triaca V, Amadoro G, Latina V, Calissano P, Travaglia A, Nicoletti VG, La Mendola D, Rizzarelli E. Cells 8 E301 (2019)
  16. Highly precise protein-protein interaction prediction based on consensus between template-based and de novo docking methods. Ohue M, Matsuzaki Y, Shimoda T, Ishida T, Akiyama Y. BMC Proc 7 S6 (2013)
  17. Molecular simulation of the binding of nerve growth factor peptide mimics to the receptor tyrosine kinase A. Berrera M, Cattaneo A, Carloni P. Biophys J 91 2063-2071 (2006)
  18. Identification of critical residues within the conserved and specificity patches of nerve growth factor leading to survival or differentiation. Mahapatra S, Mehta H, Woo SB, Neet KE. J Biol Chem 284 33600-33613 (2009)
  19. The conundrum of the high-affinity NGF binding site formation unveiled? Covaceuszach S, Konarev PV, Cassetta A, Paoletti F, Svergun DI, Lamba D, Cattaneo A. Biophys J 108 687-697 (2015)
  20. Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody. Covaceuszach S, Marinelli S, Krastanova I, Ugolini G, Pavone F, Lamba D, Cattaneo A. PLoS One 7 e32212 (2012)
  21. A conservation and biophysics guided stochastic approach to refining docked multimeric proteins. Akbal-Delibas B, Haspel N. BMC Struct Biol 13 Suppl 1 S7 (2013)
  22. Comparison of nerve growth factor receptor binding models using heterodimeric muteins. Mehta HM, Woo SB, Neet KE. J Neurosci Res 90 2259-2271 (2012)
  23. Generation of a high-fidelity antibody against nerve growth factor using library scanning mutagenesis and validation with structures of the initial and optimized Fab-antigen complexes. La Porte SL, Eigenbrot C, Ultsch M, Ho WH, Foletti D, Forgie A, Lindquist KC, Shelton DL, Pons J. MAbs 6 1059-1068 (2014)
  24. HopDock: a probabilistic search algorithm for decoy sampling in protein-protein docking. Hashmi I, Shehu A. Proteome Sci 11 S6 (2013)
  25. Predicting a double mutant in the twilight zone of low homology modeling for the skeletal muscle voltage-gated sodium channel subunit beta-1 (Nav1.4 β1). Scior T, Paiz-Candia B, Islas ÁA, Sánchez-Solano A, Millan-Perez Peña L, Mancilla-Simbro C, Salinas-Stefanon EM. Comput Struct Biotechnol J 13 229-240 (2015)
  26. Design and nuclear magnetic resonance (NMR) structure determination of the second extracellular immunoglobulin tyrosine kinase A (TrkAIg2) domain construct for binding site elucidation in drug discovery. Shoemark DK, Williams C, Fahey MS, Watson JJ, Tyler SJ, Scoltock SJ, Ellis RZ, Wickenden E, Burton AJ, Hemmings JL, Bailey CD, Dawbarn D, Jane DE, Willis CL, Sessions RB, Allen SJ, Crump MP. J Med Chem 58 767-777 (2015)
  27. Role of the conformational versatility of the neurotrophin N-terminal regions in their recognition by Trk receptors. Stanzione F, Esposito L, Paladino A, Pedone C, Morelli G, Vitagliano L. Biophys J 99 2273-2278 (2010)
  28. The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. Chakraborty S, Rendón-Ramírez A, Ásgeirsson B, Dutta M, Ghosh AS, Oda M, Venkatramani R, Rao BJ, Dandekar AM, Goñi FM. F1000Res 2 286 (2013)
  29. Unveiling functional motions based on point mutations in biased signaling systems: A normal mode study on nerve growth factor bound to TrkA. Resende-Lara PT, Perahia D, Scott AL, Braz ASK. PLoS One 15 e0231542 (2020)
  30. Development and Biological Characterization of a Novel Selective TrkA Agonist with Neuroprotective Properties against Amyloid Toxicity. Rogdakis T, Charou D, Latorrata A, Papadimitriou E, Tsengenes A, Athanasiou C, Papadopoulou M, Chalikiopoulou C, Katsila T, Ramos I, Prousis KC, Wade RC, Sidiropoulou K, Calogeropoulou T, Gravanis A, Charalampopoulos I. Biomedicines 10 614 (2022)
  31. Effect of conformation sampling strategies in genetic algorithm for multiple protein docking. Esquivel-Rodríguez J, Kihara D. BMC Proc 6 Suppl 7 S4 (2012)
  32. Endogenous modulators of neurotrophin signaling: Landscape of the transient ATP-NGF interactions. Paoletti F, Merzel F, Cassetta A, Ogris I, Covaceuszach S, Grdadolnik J, Lamba D, Golič Grdadolnik S. Comput Struct Biotechnol J 19 2938-2949 (2021)
  33. CARDIO-PRED: an in silico tool for predicting cardiovascular-disorder associated proteins. Jain P, Thukral N, Gahlot LK, Hasija Y. Syst Synth Biol 9 55-66 (2015)
  34. Computational Insights into the Sequence-Activity Relationships of the NGF(1-14) Peptide by Molecular Dynamics Simulations. Vittorio S, Manelfi C, Gervasoni S, Beccari AR, Pedretti A, Vistoli G, Talarico C. Cells 11 2808 (2022)
  35. Intrinsically disordered regions couple the ligand binding and kinase activation of Trk neurotrophin receptors. Kot EF, Franco ML, Vasilieva EV, Shabalkina AV, Arseniev AS, Goncharuk SA, Mineev KS, Vilar M. iScience 25 104348 (2022)


Reviews citing this publication (53)

  1. Neurotrophins: roles in neuronal development and function. Huang EJ, Reichardt LF. Annu Rev Neurosci 24 677-736 (2001)
  2. Cell signaling by receptor tyrosine kinases. Lemmon MA, Schlessinger J. Cell 141 1117-1134 (2010)
  3. Trk receptors: roles in neuronal signal transduction. Huang EJ, Reichardt LF. Annu Rev Biochem 72 609-642 (2003)
  4. Neurotrophin-regulated signalling pathways. Reichardt LF. Philos Trans R Soc Lond B Biol Sci 361 1545-1564 (2006)
  5. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Arkin MR, Wells JA. Nat Rev Drug Discov 3 301-317 (2004)
  6. Nerve growth factor signaling, neuroprotection, and neural repair. Sofroniew MV, Howe CL, Mobley WC. Annu Rev Neurosci 24 1217-1281 (2001)
  7. Trk receptors: mediators of neurotrophin action. Patapoutian A, Reichardt LF. Curr Opin Neurobiol 11 272-280 (2001)
  8. The discovery of receptor tyrosine kinases: targets for cancer therapy. Gschwind A, Fischer OM, Ullrich A. Nat Rev Cancer 4 361-370 (2004)
  9. Protein tyrosine kinase structure and function. Hubbard SR, Till JH. Annu Rev Biochem 69 373-398 (2000)
  10. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Murer MG, Yan Q, Raisman-Vozari R. Prog Neurobiol 63 71-124 (2001)
  11. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S. Mol Cell 12 541-552 (2003)
  12. 3D domain swapping: as domains continue to swap. Liu Y, Eisenberg D. Protein Sci 11 1285-1299 (2002)
  13. Structure and function of Toll receptors and their ligands. Gay NJ, Gangloff M. Annu Rev Biochem 76 141-165 (2007)
  14. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK. Pharmacol Ther 138 155-175 (2013)
  15. Selectivity in neurotrophin signaling: theme and variations. Segal RA. Annu Rev Neurosci 26 299-330 (2003)
  16. Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease. Longo FM, Massa SM. Nat Rev Drug Discov 12 507-525 (2013)
  17. Apoptosis: biochemical aspects and clinical implications. Kiechle FL, Zhang X. Clin Chim Acta 326 27-45 (2002)
  18. Neurotrophins and neurodegeneration. Dawbarn D, Allen SJ. Neuropathol Appl Neurobiol 29 211-230 (2003)
  19. Targeting nerve growth factor in pain: what is the therapeutic potential? Watson JJ, Allen SJ, Dawbarn D. BioDrugs 22 349-359 (2008)
  20. Allosteric Modulation as a Unifying Mechanism for Receptor Function and Regulation. Changeux JP, Christopoulos A. Cell 166 1084-1102 (2016)
  21. Tyrosine kinase receptors as attractive targets of cancer therapy. Bennasroune A, Gardin A, Aunis D, Crémel G, Hubert P. Crit Rev Oncol Hematol 50 23-38 (2004)
  22. The insulin receptor: a prototype for dimeric, allosteric membrane receptors? De Meyts P. Trends Biochem Sci 33 376-384 (2008)
  23. The nerve growth factor and its receptors in airway inflammatory diseases. Freund-Michel V, Frossard N. Pharmacol Ther 117 52-76 (2008)
  24. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. Mol Cancer 17 34 (2018)
  25. Trophic factors: An evolutionary cul-de-sac or door into higher neuronal function? Chao MV. J Neurosci Res 59 353-355 (2000)
  26. Nerve growth factor and its receptors in asthma and inflammation. Frossard N, Freund V, Advenier C. Eur J Pharmacol 500 453-465 (2004)
  27. Proteolytic processing of the p75 neurotrophin receptor: A prerequisite for signalling?: Neuronal life, growth and death signalling are crucially regulated by intra-membrane proteolysis and trafficking of p75(NTR). Skeldal S, Matusica D, Nykjaer A, Coulson EJ. Bioessays 33 614-625 (2011)
  28. Signaling receptome: a genomic and evolutionary perspective of plasma membrane receptors involved in signal transduction. Ben-Shlomo I, Yu Hsu S, Rauch R, Kowalski HW, Hsueh AJ. Sci STKE 2003 RE9 (2003)
  29. Mechanistic diversity of cytokine receptor signaling across cell membranes. Stroud RM, Wells JA. Sci STKE 2004 re7 (2004)
  30. Evolving better brains: a need for neurotrophins? Jaaro H, Beck G, Conticello SG, Fainzilber M. Trends Neurosci 24 79-85 (2001)
  31. Neurotrophins and Proneurotrophins: Focus on Synaptic Activity and Plasticity in the Brain. Gibon J, Barker PA. Neuroscientist 23 587-604 (2017)
  32. Origin and evolution of the Trk family of neurotrophic receptors. Benito-Gutiérrez E, Garcia-Fernàndez J, Comella JX. Mol Cell Neurosci 31 179-192 (2006)
  33. Protein-protein interactions in receptor activation and intracellular signalling. Blundell TL, Burke DF, Chirgadze D, Dhanaraj V, Hyvönen M, Innis CA, Parisini E, Pellegrini L, Sayed M, Sibanda BL. Biol Chem 381 955-959 (2000)
  34. Structural studies of GDNF family ligands with their receptors-Insights into ligand recognition and activation of receptor tyrosine kinase RET. Wang X. Biochim Biophys Acta 1834 2205-2212 (2013)
  35. Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor. Eibl JK, Strasser BC, Ross GM. Neurochem Int 61 1266-1275 (2012)
  36. Cell surface receptors. Deller MC, Yvonne Jones E. Curr Opin Struct Biol 10 213-219 (2000)
  37. Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy. Pramanik S, Sulistio YA, Heese K. Mol Neurobiol 54 7401-7459 (2017)
  38. Neurotrophic factors and their inhibitors in chronic pain treatment. Kelleher JH, Tewari D, McMahon SB. Neurobiol Dis 97 127-138 (2017)
  39. Allosteric modulation as a unifying mechanism for receptor function and regulation. Changeux JP, Christopoulos A. Diabetes Obes Metab 19 Suppl 1 4-21 (2017)
  40. Assembly and activation of neurotrophic factor receptor complexes. Simi A, Ibáñez CF. Dev Neurobiol 70 323-331 (2010)
  41. Role of transient receptor potential and acid-sensing ion channels in peripheral inflammatory pain. White JP, Cibelli M, Rei Fidalgo A, Paule CC, Noormohamed F, Urban L, Maze M, Nagy I. Anesthesiology 112 729-741 (2010)
  42. Local versus long-range neurotrophin receptor signalling: endosomes are not just carriers for axonal transport. Matusica D, Coulson EJ. Semin Cell Dev Biol 31 57-63 (2014)
  43. Tropomyosin-receptor-kinases signaling in the nervous system. Stoleru B, Popescu AM, Tache DE, Neamtu OM, Emami G, Tataranu LG, Buteica AS, Dricu A, Purcaru SO. Maedica (Bucur) 8 43-48 (2013)
  44. Ligand-induced dynamics of neurotrophin receptors investigated by single-molecule imaging approaches. Marchetti L, Luin S, Bonsignore F, de Nadai T, Beltram F, Cattaneo A. Int J Mol Sci 16 1949-1979 (2015)
  45. Nerve Growth Factor in Alcohol Use Disorders. Ceci FM, Ferraguti G, Petrella C, Greco A, Ralli M, Iannitelli A, Carito V, Tirassa P, Chaldakov GN, Messina MP, Ceccanti M, Fiore M. Curr Neuropharmacol 19 45-60 (2021)
  46. Role of NGF and its receptors in wound healing (Review). Liu Z, Wu H, Huang S. Exp Ther Med 21 599 (2021)
  47. The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma. Davidson B, Risberg B, Berner A, Bedrossian CW, Reich R. Semin Diagn Pathol 23 35-43 (2006)
  48. Peptides Derived from Growth Factors to Treat Alzheimer's Disease. Gascon S, Jann J, Langlois-Blais C, Plourde M, Lavoie C, Faucheux N. Int J Mol Sci 22 6071 (2021)
  49. It Takes More than Two to Tango: Complex, Hierarchal, and Membrane-Modulated Interactions in the Regulation of Receptor Tyrosine Kinases. Kovacs T, Zakany F, Nagy P. Cancers (Basel) 14 944 (2022)
  50. Putting two and two together: crystal structure of the FGF-receptor complex. Wiesmann C, de Vos AM. Structure 7 R251-5 (1999)
  51. Neurotrophin mimetics and tropomyosin kinase receptors: a futuristic pharmacological tool for Parkinson's. J JB, Palathoti N, Dhanasekaran M, Sivasamy R, Ponnusankar S, Dhanabal SP, Sankar V, Justin A. Neurol Sci 44 2265-2275 (2023)
  52. The role of neurotrophic factors in novel, rapid psychiatric treatments. Kim J, He MJ, Widmann AK, Lee FS. Neuropsychopharmacology (2023)
  53. [Precursors and propeptides of neurotrophic factors as the modulators of biological activity of its mature forms]. Rafieva LM, Shubin AV, Gasanov EV. Bioorg Khim 38 515-523 (2012)

Articles citing this publication (125)

  1. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S. Cell 110 775-787 (2002)
  2. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. Teng HK, Teng KK, Lee R, Wright S, Tevar S, Almeida RD, Kermani P, Torkin R, Chen ZY, Lee FS, Kraemer RT, Nykjaer A, Hempstead BL. J Neurosci 25 5455-5463 (2005)
  3. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, Burgess AW, Ward CW. Cell 110 763-773 (2002)
  4. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA. Mol Cell 11 507-517 (2003)
  5. Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix. Sakiyama-Elbert SE, Hubbell JA. J Control Release 69 149-158 (2000)
  6. Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner. Salinas M, Diaz R, Abraham NG, Ruiz de Galarreta CM, Cuadrado A, Cuadrado A. J Biol Chem 278 13898-13904 (2003)
  7. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Wehrman T, He X, Raab B, Dukipatti A, Blau H, Garcia KC. Neuron 53 25-38 (2007)
  8. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Gherardi E, Sandin S, Petoukhov MV, Finch J, Youles ME, Ofverstedt LG, Miguel RN, Blundell TL, Vande Woude GF, Skoglund U, Svergun DI. Proc Natl Acad Sci U S A 103 4046-4051 (2006)
  9. The Sema domain of Met is necessary for receptor dimerization and activation. Kong-Beltran M, Stamos J, Wickramasinghe D. Cancer Cell 6 75-84 (2004)
  10. Structural basis of receptor sharing by interleukin 17 cytokines. Ely LK, Fischer S, Garcia KC. Nat Immunol 10 1245-1251 (2009)
  11. Structural insights into the Slit-Robo complex. Morlot C, Thielens NM, Ravelli RB, Hemrika W, Romijn RA, Gros P, Cusack S, McCarthy AA. Proc Natl Acad Sci U S A 104 14923-14928 (2007)
  12. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Gherardi E, Youles ME, Miguel RN, Blundell TL, Iamele L, Gough J, Bandyopadhyay A, Hartmann G, Butler PJ. Proc Natl Acad Sci U S A 100 12039-12044 (2003)
  13. GDNF and GFRalpha1 promote formation of neuronal synapses by ligand-induced cell adhesion. Ledda F, Paratcha G, Sandoval-Guzmán T, Ibáñez CF. Nat Neurosci 10 293-300 (2007)
  14. Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (MuSK). Zhang W, Coldefy AS, Hubbard SR, Burden SJ. J Biol Chem 286 40624-40630 (2011)
  15. Design of potent peptide mimetics of brain-derived neurotrophic factor. O'Leary PD, Hughes RA. J Biol Chem 278 25738-25744 (2003)
  16. Crystal structure of the neurotrophin-3 and p75NTR symmetrical complex. Gong Y, Cao P, Yu HJ, Jiang T. Nature 454 789-793 (2008)
  17. Time course and nerve growth factor dependence of inflammation-induced alterations in electrophysiological membrane properties in nociceptive primary afferent neurons. Djouhri L, Dawbarn D, Robertson A, Newton R, Lawson SN. J Neurosci 21 8722-8733 (2001)
  18. Mechanisms of activation of receptor tyrosine kinases: monomers or dimers. Maruyama IN. Cells 3 304-330 (2014)
  19. Antibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without tolerance. Wild KD, Bian D, Zhu D, Davis J, Bannon AW, Zhang TJ, Louis JC. J Pharmacol Exp Ther 322 282-287 (2007)
  20. Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases. Liu H, Chen X, Focia PJ, He X. EMBO J 26 891-901 (2007)
  21. TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor. Arevalo JC, Conde B, Hempstead BL, Chao MV, Martin-Zanca D, Perez P. Mol Cell Biol 20 5908-5916 (2000)
  22. Specificity in Trk receptor:neurotrophin interactions: the crystal structure of TrkB-d5 in complex with neurotrophin-4/5. Banfield MJ, Naylor RL, Robertson AG, Allen SJ, Dawbarn D, Brady RL. Structure 9 1191-1199 (2001)
  23. The secreted brain-derived neurotrophic factor precursor pro-BDNF binds to TrkB and p75NTR but not to TrkA or TrkC. Fayard B, Loeffler S, Weis J, Vögelin E, Krüttgen A. J Neurosci Res 80 18-28 (2005)
  24. Taking pain out of NGF: a "painless" NGF mutant, linked to hereditary sensory autonomic neuropathy type V, with full neurotrophic activity. Capsoni S, Covaceuszach S, Marinelli S, Ceci M, Bernardo A, Minghetti L, Ugolini G, Pavone F, Cattaneo A. PLoS One 6 e17321 (2011)
  25. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Davidson B, Reich R, Lazarovici P, Ann Flørenes V, Nielsen S, Nesland JM. Breast Cancer Res Treat 83 119-128 (2004)
  26. Biochemical and biophysical investigation of the brain-derived neurotrophic factor mimetic 7,8-dihydroxyflavone in the binding and activation of the TrkB receptor. Liu X, Obianyo O, Chan CB, Huang J, Xue S, Yang JJ, Zeng F, Goodman M, Ye K. J Biol Chem 289 27571-27584 (2014)
  27. The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition. Bertrand T, Kothe M, Liu J, Dupuy A, Rak A, Berne PF, Davis S, Gladysheva T, Valtre C, Crenne JY, Mathieu M. J Mol Biol 423 439-453 (2012)
  28. A novel NGF mutation clarifies the molecular mechanism and extends the phenotypic spectrum of the HSAN5 neuropathy. Carvalho OP, Thornton GK, Hertecant J, Houlden H, Nicholas AK, Cox JJ, Rielly M, Al-Gazali L, Woods CG. J Med Genet 48 131-135 (2011)
  29. Expression pattern of LRR and Ig domain-containing protein (LRRIG protein) in the early mouse embryo. Homma S, Shimada T, Hikake T, Yaginuma H. Gene Expr Patterns 9 1-26 (2009)
  30. Intranasal "painless" human Nerve Growth Factor [corrected] slows amyloid neurodegeneration and prevents memory deficits in App X PS1 mice. Capsoni S, Marinelli S, Ceci M, Vignone D, Amato G, Malerba F, Paoletti F, Meli G, Viegi A, Pavone F, Cattaneo A. PLoS One 7 e37555 (2012)
  31. Isolation of recombinant BMP receptor IA ectodomain and its 2:1 complex with BMP-2. Kirsch T, Nickel J, Sebald W. FEBS Lett 468 215-219 (2000)
  32. Crystal structure of the agrin-responsive immunoglobulin-like domains 1 and 2 of the receptor tyrosine kinase MuSK. Stiegler AL, Burden SJ, Hubbard SR. J Mol Biol 364 424-433 (2006)
  33. Olfactory sensory neurons mediate ultrarapid antiviral immune responses in a TrkA-dependent manner. Sepahi A, Kraus A, Casadei E, Johnston CA, Galindo-Villegas J, Kelly C, García-Moreno D, Muñoz P, Mulero V, Huertas M, Salinas I. Proc Natl Acad Sci U S A 116 12428-12436 (2019)
  34. Ternary complex with Trk, p75, and an ankyrin-rich membrane spanning protein. Chang MS, Arevalo JC, Chao MV. J Neurosci Res 78 186-192 (2004)
  35. Dependence of neurotrophic factor activation of Trk tyrosine kinase receptors on cellular sialidase. Woronowicz A, Amith SR, De Vusser K, Laroy W, Contreras R, Basta S, Szewczuk MR. Glycobiology 17 10-24 (2007)
  36. Regulatory effect of nerve growth factor in alpha9beta1 integrin-dependent progression of glioblastoma. Brown MC, Staniszewska I, Lazarovici P, Tuszynski GP, Del Valle L, Marcinkiewicz C. Neuro Oncol 10 968-980 (2008)
  37. A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist. Tolbert WD, Daugherty J, Gao C, Xie Q, Miranti C, Gherardi E, Vande Woude G, Xu HE. Proc Natl Acad Sci U S A 104 14592-14597 (2007)
  38. Intrinsic structural disorder of mouse proNGF. Paoletti F, Covaceuszach S, Konarev PV, Gonfloni S, Malerba F, Schwarz E, Svergun DI, Cattaneo A, Lamba D. Proteins 75 990-1009 (2009)
  39. Sequence and structural determinants of strand swapping in cadherin domains: do all cadherins bind through the same adhesive interface? Posy S, Shapiro L, Honig B. J Mol Biol 378 954-968 (2008)
  40. Construction of a mutated pro-nerve growth factor resistant to degradation and suitable for biophysical and cellular utilization. Pagadala PC, Dvorak LA, Neet KE. Proc Natl Acad Sci U S A 103 17939-17943 (2006)
  41. Design of a conformationally defined and proteolytically stable circular mimetic of brain-derived neurotrophic factor. Fletcher JM, Morton CJ, Zwar RA, Murray SS, O'Leary PD, Hughes RA. J Biol Chem 283 33375-33383 (2008)
  42. A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation. Arevalo JC, Conde B, Hempstead BI, Chao MV, Martín-Zanca D, Pérez P. Oncogene 20 1229-1234 (2001)
  43. In vitro receptor binding properties of a "painless" NGF mutein, linked to hereditary sensory autonomic neuropathy type V. Covaceuszach S, Capsoni S, Marinelli S, Pavone F, Ceci M, Ugolini G, Vignone D, Amato G, Paoletti F, Lamba D, Cattaneo A. Biochem Biophys Res Commun 391 824-829 (2010)
  44. Natural history and functional divergence of protein tyrosine kinases. Gu J, Gu X. Gene 317 49-57 (2003)
  45. Antibody binding regions on human nerve growth factor identified by homolog- and alanine-scanning mutagenesis. Hongo JS, Laramee GR, Urfer R, Shelton DL, Restivo T, Sadick M, Galloway A, Chu H, Winslow JW. Hybridoma 19 215-227 (2000)
  46. Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Davidson B, Reich R, Lazarovici P, Flørenes VA, Risberg B, Nielsen S, Sert B, Bedrossian C. Lung Cancer 44 159-165 (2004)
  47. Nerve growth factor signals via preexisting TrkA receptor oligomers. Mischel PS, Umbach JA, Eskandari S, Smith SG, Gundersen CB, Zampighi GA. Biophys J 83 968-976 (2002)
  48. Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. Zaccaro MC, Lee HB, Pattarawarapan M, Xia Z, Caron A, L'Heureux PJ, Bengio Y, Burgess K, Saragovi HU. Chem Biol 12 1015-1028 (2005)
  49. TrkA receptor "hot spots" for binding of NT-3 as a heterologous ligand. Ivanisevic L, Zheng W, Woo SB, Neet KE, Saragovi HU. J Biol Chem 282 16754-16763 (2007)
  50. Distinction between differentiation, cell cycle, and apoptosis signals in PC12 cells by the nerve growth factor mutant delta9/13, which is selective for the p75 neurotrophin receptor. Hughes AL, Messineo-Jones D, Lad SP, Neet KE. J Neurosci Res 63 10-19 (2001)
  51. Novel monocyclic and bicyclic loop mimetics of brain-derived neurotrophic factor. Fletcher JM, Hughes RA. J Pept Sci 12 515-524 (2006)
  52. Nerve growth factor receptor TrkA exists as a preformed, yet inactive, dimer in living cells. Shen J, Maruyama IN. FEBS Lett 585 295-299 (2011)
  53. The mature part of proNGF induces the structure of its pro-peptide. Kliemannel M, Rattenholl A, Golbik R, Balbach J, Lilie H, Rudolph R, Schwarz E. FEBS Lett 566 207-212 (2004)
  54. A discrete domain of the human TrkB receptor defines the binding sites for BDNF and NT-4. Naylor RL, Robertson AG, Allen SJ, Sessions RB, Clarke AR, Mason GG, Burston JJ, Tyler SJ, Wilcock GK, Dawbarn D. Biochem Biophys Res Commun 291 501-507 (2002)
  55. Dissecting NGF interactions with TrkA and p75 receptors by structural and functional studies of an anti-NGF neutralizing antibody. Covaceuszach S, Cassetta A, Konarev PV, Gonfloni S, Rudolph R, Svergun DI, Lamba D, Cattaneo A. J Mol Biol 381 881-896 (2008)
  56. Identification and structure of the nerve growth factor binding site on TrkA. Robertson AG, Banfield MJ, Allen SJ, Dando JA, Mason GG, Tyler SJ, Bennett GS, Brain SD, Clarke AR, Naylor RL, Wilcock GK, Brady RL, Dawbarn D. Biochem Biophys Res Commun 282 131-141 (2001)
  57. Scaffolding protein functional sites using deep learning. Wang J, Lisanza S, Juergens D, Tischer D, Watson JL, Castro KM, Ragotte R, Saragovi A, Milles LF, Baek M, Anishchenko I, Yang W, Hicks DR, Expòsit M, Schlichthaerle T, Chun JH, Dauparas J, Bennett N, Wicky BIM, Muenks A, DiMaio F, Correia B, Ovchinnikov S, Baker D. Science 377 387-394 (2022)
  58. The inorganic perspective of nerve growth factor: interactions of Cu2+ and Zn2+ with the N-terminus fragment of nerve growth factor encompassing the recognition domain of the TrkA receptor. Travaglia A, Arena G, Fattorusso R, Isernia C, La Mendola D, Malgieri G, Nicoletti VG, Rizzarelli E. Chemistry 17 3726-3738 (2011)
  59. Neurotrophic activities of trk receptors conserved over 600 million years of evolution. Beck G, Munno DW, Levy Z, Dissel HM, Van-Minnen J, Syed NI, Fainzilber M. J Neurobiol 60 12-20 (2004)
  60. Cytokine Spatzle binds to the Drosophila immunoreceptor Toll with a neurotrophin-like specificity and couples receptor activation. Lewis M, Arnot CJ, Beeston H, McCoy A, Ashcroft AE, Gay NJ, Gangloff M. Proc Natl Acad Sci U S A 110 20461-20466 (2013)
  61. Differential activity of the nerve growth factor (NGF) antagonist PD90780 [7-(benzolylamino)-4,9-dihydro-4-methyl-9-oxo-pyrazolo[5,1-b]quinazoline-2-carboxylic acid] suggests altered NGF-p75NTR interactions in the presence of TrkA. Colquhoun A, Lawrance GM, Shamovsky IL, Riopelle RJ, Ross GM. J Pharmacol Exp Ther 310 505-511 (2004)
  62. The pro-peptide of proNGF: structure formation and intramolecular association with NGF. Kliemannel M, Golbik R, Rudolph R, Schwarz E, Lilie H. Protein Sci 16 411-419 (2007)
  63. Directed evolution of brain-derived neurotrophic factor for improved folding and expression in Saccharomyces cerevisiae. Burns ML, Malott TM, Metcalf KJ, Hackel BJ, Chan JR, Shusta EV. Appl Environ Microbiol 80 5732-5742 (2014)
  64. Non-helical DNA Triplex Forms a Unique Aptamer Scaffold for High Affinity Recognition of Nerve Growth Factor. Jarvis TC, Davies DR, Hisaminato A, Resnicow DI, Gupta S, Waugh SM, Nagabukuro A, Wadatsu T, Hishigaki H, Gawande B, Zhang C, Wolk SK, Mayfield WS, Nakaishi Y, Burgin AB, Stewart LJ, Edwards TE, Gelinas AD, Schneider DJ, Janjic N. Structure 23 1293-1304 (2015)
  65. Lysophosphatidylcholine enhances NGF-induced MAPK and Akt signals through the extracellular domain of TrkA in PC12 cells. Wuhanqimuge, Itakura A, Matsuki Y, Tanaka M, Arioka M. FEBS Open Bio 3 243-251 (2013)
  66. ProNGF inhibits NGF-mediated TrkA activation in PC12 cells. Sobottka B, Reinhardt D, Brockhaus M, Jacobsen H, Metzger F. J Neurochem 107 1294-1303 (2008)
  67. Selective and differential interactions of BNN27, a novel C17-spiroepoxy steroid derivative, with TrkA receptors, regulating neuronal survival and differentiation. Pediaditakis I, Efstathopoulos P, Prousis KC, Zervou M, Arévalo JC, Alexaki VI, Nikoletopoulou V, Karagianni E, Potamitis C, Tavernarakis N, Chavakis T, Margioris AN, Venihaki M, Calogeropoulou T, Charalampopoulos I, Gravanis A. Neuropharmacology 111 266-282 (2016)
  68. Post-translational modification accounts for the presence of varied forms of nerve growth factor in Australian elapid snake venoms. Earl ST, Birrell GW, Wallis TP, St Pierre LD, Masci PP, de Jersey J, Gorman JJ, Lavin MF. Proteomics 6 6554-6565 (2006)
  69. The receptor tyrosine kinase TrkB signals without dimerization at the plasma membrane. Zahavi EE, Steinberg N, Altman T, Chein M, Joshi Y, Gradus-Pery T, Perlson E. Sci Signal 11 eaao4006 (2018)
  70. Trypanosoma cruzi promotes neuronal and glial cell survival through the neurotrophic receptor TrkC. Weinkauf C, Pereiraperrin M. Infect Immun 77 1368-1375 (2009)
  71. Deciphering Molecular Mechanism of the Neuropharmacological Action of Fucosterol through Integrated System Pharmacology and In Silico Analysis. Hannan MA, Dash R, Sohag AAM, Moon IS. Mar Drugs 17 E639 (2019)
  72. TDP6, a brain-derived neurotrophic factor-based trkB peptide mimetic, promotes oligodendrocyte myelination. Wong AW, Giuffrida L, Wood R, Peckham H, Gonsalvez D, Murray SS, Hughes RA, Xiao J. Mol Cell Neurosci 63 132-140 (2014)
  73. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. Yan W, Lakkaniga NR, Carlomagno F, Santoro M, McDonald NQ, Lv F, Gunaganti N, Frett B, Li HY. J Med Chem 62 1731-1760 (2019)
  74. The crystal structure of the human titin:obscurin complex reveals a conserved yet specific muscle M-band zipper module. Pernigo S, Fukuzawa A, Pandini A, Holt M, Kleinjung J, Gautel M, Steiner RA. J Mol Biol 427 718-736 (2015)
  75. A synthetic peptide containing loop 4 of nerve growth factor for targeted gene delivery. Zeng J, Too HP, Ma Y, Luo ES, Wang S. J Gene Med 6 1247-1256 (2004)
  76. Conformational characterization of nerve growth factor-β reveals that its regulatory pro-part domain stabilizes three loop regions in its mature part. Trabjerg E, Kartberg F, Christensen S, Rand KD. J Biol Chem 292 16665-16676 (2017)
  77. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight. Covaceuszach S, Cattaneo A, Lamba D. Proteins 58 717-727 (2005)
  78. The structural biology of growth factor receptor activation. Harmer NJ, Chirgadze D, Hyun Kim K, Pellegrini L, Blundell TL. Biophys Chem 100 545-553 (2003)
  79. cDNA sequence and molecular modeling of a nerve growth factor from Bothrops jararacussu venomous gland. Kashima S, Soares AM, Roberto PG, Pereira JO, Astolfi-Filho S, Cintra AO, Fontes MR, Giglio JR, de Castro França S. Biochimie 84 675-680 (2002)
  80. Characterization of nerve growth factors (NGFs) from snake venoms by use of a novel, quantitative bioassay utilizing pheochromocytoma (PC12) cells overexpressing human trkA receptors. Katzir I, Shani J, Goshen G, Sela J, Ninary E, Dogonovski AM, Shabashov D, Inoue S, Ikeda K, Hayashi K, Gorinstein S, Deutsch J, Lazarovici P. Toxicon 42 481-490 (2003)
  81. Nerve growth factor receptor-mediated gene transfer. Ma N, Wu SS, Ma YX, Wang X, Zeng J, Tong G, Huang Y, Wang S. Mol Ther 9 270-281 (2004)
  82. Sodium depletion increases sympathetic neurite outgrowth and expression of a novel TMEM35 gene-derived protein (TUF1) in the rat adrenal zona glomerulosa. Tran PV, Georgieff MK, Engeland WC. Endocrinology 151 4852-4860 (2010)
  83. Structural and functional insights into lipid-bound nerve growth factors. Tong Q, Wang F, Zhou HZ, Sun HL, Song H, Shu YY, Gong Y, Zhang WT, Cai TX, Yang FQ, Tang J, Jiang T. FASEB J 26 3811-3821 (2012)
  84. Up-regulation of pro-nerve growth factor, neurotrophin receptor p75, and sortilin is associated with retrovirus-induced spongiform encephalomyelopathy. Stoica G, Lungu G, Kim HT, Wong PK. Brain Res 1208 204-216 (2008)
  85. A close look at axonal transport: Cargos slow down when crossing stationary organelles. Che DL, Chowdary PD, Cui B. Neurosci Lett 610 110-116 (2016)
  86. Enhanced gene delivery to PC12 cells by a cationic polypeptide. Zeng J, Wang S. Biomaterials 26 679-686 (2005)
  87. Peptides derived from the solvent-exposed loops 3 and 4 of BDNF bind TrkB and p75(NTR) receptors and stimulate neurite outgrowth and survival. Fobian K, Owczarek S, Budtz C, Bock E, Berezin V, Pedersen MV. J Neurosci Res 88 1170-1181 (2010)
  88. Structural insights into SorCS2-Nerve Growth Factor complex formation. Leloup N, Chataigner LMP, Janssen BJC. Nat Commun 9 2979 (2018)
  89. Deletion of novel protein TMEM35 alters stress-related functions and impairs long-term memory in mice. Kennedy BC, Dimova JG, Dakoji S, Yuan LL, Gewirtz JC, Tran PV. Am J Physiol Regul Integr Comp Physiol 311 R166-78 (2016)
  90. Designing allosteric peptide ligands targeting a globular protein. Selz KA, Samoylova TI, Samoylov AM, Vodyanoy VJ, Mandell AJ. Biopolymers 85 38-59 (2007)
  91. Research Support, Non-U.S. Gov't Nerve growth factor and the vanilloid receptor: partners in crime? van den Worm E, Nijkamp FP, Engels F. Clin Exp Allergy 34 996-1000 (2004)
  92. Oxidative folding of nerve growth factor can be mediated by the pro-peptide of neurotrophin-3. Hauburger A, Kliemannel M, Madsen P, Rudolph R, Schwarz E. FEBS Lett 581 4159-4164 (2007)
  93. Conformational plasticity of proNGF. Paoletti F, Malerba F, Kelly G, Noinville S, Lamba D, Cattaneo A, Pastore A. PLoS One 6 e22615 (2011)
  94. Cyclic-AMP response element-based signaling assays for characterization of Trk family tyrosine kinases modulators. Zhang J, Chen D, Gong X, Ling H, Zhang G, Wood A, Heinrich J, Cho S. Neurosignals 15 26-39 (2006)
  95. Growth factor choice is critical for successful functionalization of nanoparticles. Pinkernelle J, Raffa V, Calatayud MP, Goya GF, Riggio C, Keilhoff G. Front Neurosci 9 305 (2015)
  96. Neural-endocrine mechanisms of respiratory syncytial virus-associated asthma in a rat model. Li QG, Wu XR, Li XZ, Yu J, Xia Y, Wang AP, Wang J. Genet Mol Res 11 2780-2789 (2012)
  97. Transient signaling of Erk1/2, Akt and PLCgamma induced by nerve growth factor in brain capillary endothelial cells. Lecht S, Arien-Zakay H, Wagenstein Y, Inoue S, Marcinkiewicz C, Lelkes PI, Lazarovici P. Vascul Pharmacol 53 107-114 (2010)
  98. Generation of a novel artificial TrkB agonist, BM17d99, using T7 phage-displayed random peptide libraries. Ohnishi T, Sakamoto K, Asami-Odaka A, Nakamura K, Shimizu A, Ito T, Asami T, Ohtaki T, Inooka H. Biochem Biophys Res Commun 483 101-106 (2017)
  99. Structural basis of the transmembrane domain dimerization and rotation in the activation mechanism of the TRKA receptor by nerve growth factor. Franco ML, Nadezhdin KD, Goncharuk SA, Mineev KS, Arseniev AS, Vilar M. J Biol Chem 295 275-286 (2020)
  100. hNGF Peptides Elicit the NGF-TrkA Signalling Pathway in Cholinergic Neurons and Retain Full Neurotrophic Activity in the DRG Assay. Triaca V, Fico E, Sposato V, Caioli S, Ciotti MT, Zona C, Mercanti D, La Mendola D, Satriano C, Rizzarelli E, Tirassa P, Calissano P. Biomolecules 10 E216 (2020)
  101. Anti-apoptotic effect of nerve growth factor is lost in congenital insensitivity to pain with anhidrosis (CIPA) B lymphocytes. Sato Y, Tsuboi Y, Kurosawa H, Sugita K, Eguchi M. J Clin Immunol 24 302-308 (2004)
  102. Conformational Rigidity within Plasticity Promotes Differential Target Recognition of Nerve Growth Factor. Paoletti F, de Chiara C, Kelly G, Covaceuszach S, Malerba F, Yan R, Lamba D, Cattaneo A, Pastore A. Front Mol Biosci 3 83 (2016)
  103. Identification of amino acid residues of nerve growth factor important for neurite outgrowth in human dorsal root ganglion neurons. Dahlström M, Nordvall G, Sundström E, Åkesson E, Tegerstedt G, Eriksdotter M, Forsell P. Eur J Neurosci 50 3487-3501 (2019)
  104. Tumor necrosis factor-related apoptosis-inducing ligand reduces the expression of the neuroprotective Na+ /Ca2+ exchanger isoform NCX3 in human neuroblastoma SH-SY5Y cells. Di Benedetto G, Valerio O, Lariccia V, Burgaletto C, Lempereur L, Parenti C, Zanghì GN, Matteucci A, Amoroso S, Bernardini R, Cantarella G. FEBS J 286 737-749 (2019)
  105. Tyrosine kinase activity of nerve growth factor and estrogen in embryonic septal neurons cultured from the rat. Green D, Jonusas A, Montague JR, Mudd LM. Neurochem Res 27 1699-1705 (2002)
  106. Ubiquitin Associates with the N-Terminal Domain of Nerve Growth Factor: The Role of Copper(II) Ions. Lanza V, Travaglia A, Malgieri G, Fattorusso R, Grasso G, Di Natale G, Zito V, Arena G, Milardi D, Rizzarelli E. Chemistry 22 17767-17775 (2016)
  107. Neurotrophin, p75, and Trk Signaling Module in the Developing Nervous System of the Marine Annelid Platynereis dumerilii. Lauri A, Bertucci P, Arendt D. Biomed Res Int 2016 2456062 (2016)
  108. The 3rd degree of biomimetism: associating the cavity effect, ZnII coordination and internal base assistance for guest binding and activation. Parrot A, Collin S, Bruylants G, Reinaud O. Chem Sci 9 5479-5487 (2018)
  109. 2-alkyl-2-carboxyazetidines as γ-turn inducers: incorporation into neurotrophin fragments. Baeza JL, Bonache MA, García-López MT, González-Muñiz R, Martín-Martínez M. Amino Acids 39 1299-1307 (2010)
  110. 3β, 6β-dichloro-5-hydroxy-5α-cholestane facilitates neuronal development through modulating TrkA signaling regulated proteins in primary hippocampal neuron. Hannan MA, Haque MN, Dash R, Alam M, Moon IS. Sci Rep 9 18919 (2019)
  111. Extracellular Juxtamembrane Motif Critical for TrkB Preformed Dimer and Activation. Shen J, Sun D, Shao J, Chen Y, Pang K, Guo W, Lu B. Cells 8 E932 (2019)
  112. A C-terminal cysteine residue is required for peptide-based inhibition of the NGF/TrkA interaction at nM concentrations: implications for peptide-based analgesics. Poole AJ, Frigotto L, Smith ME, Baar C, Ivanova-Berndt G, Jaulent A, Stace C, Ullman CG, Hine AV. Sci Rep 9 930 (2019)
  113. Design, synthesis and biological evaluation of pyrazolo[3,4-b]pyridine derivatives as TRK inhibitors. Liu N, Wang X, Fu Q, Qin Q, Wu T, Lv R, Zhao D, Cheng M. RSC Med Chem 14 85-102 (2023)
  114. In vitro evidence for post-insult neuroprotective activity of an evolutionarily conserved motif against excitotoxic neuronal cell death. Tran PV. Neuroreport 30 213-216 (2019)
  115. Soluble Expression of Recombinant Nerve Growth Factor in Cytoplasm of Escherichia coli. Shamriz S, Ofoghi H, Amini-Bayat Z. Iran J Biotechnol 14 16-22 (2016)
  116. Structure of a meiosis-specific complex central to BRCA2 localization at recombination sites. Pendlebury DF, Zhang J, Agrawal R, Shibuya H, Nandakumar J. Nat Struct Mol Biol 28 671-680 (2021)
  117. Crystallization and preliminary X-ray diffraction studies of cobra venom beta-nerve growth factor. Gu L, Shen Y, Xu S, Shu Y, Jiang T, Lin Z. Biochem Biophys Res Commun 297 1008-1010 (2002)
  118. Encapsulation of β-NGF in injectable microrods for localized delivery accelerates endochondral fracture repair. Rivera KO, Cuylear DL, Duke VR, O'Hara KM, Zhong JX, Elghazali NA, Finbloom JA, Kharbikar BN, Kryger AN, Miclau T, Marcucio RS, Bahney CS, Desai TA. Front Bioeng Biotechnol 11 1190371 (2023)
  119. Endothelial TrkA coordinates vascularization and innervation in thermogenic adipose tissue and can be targeted to control metabolism. Daquinag AC, Gao Z, Yu Y, Kolonin MG. Mol Metab 63 101544 (2022)
  120. Interaction between a Novel Oligopeptide Fragment of the Human Neurotrophin Receptor TrkB Ectodomain D5 and the C-Terminal Fragment of Tetanus Neurotoxin. Candalija A, Scior T, Rackwitz HR, Ruiz-Castelan JE, Martinez-Laguna Y, Aguilera J. Molecules 26 3988 (2021)
  121. Lack of association between TrkA single nucleotide polymorphisms and sporadic Alzheimer's disease in a Japanese population. Sakasegawa Y, Kishida H, Sakurai M, Asada T, Kinoshita T, Goto Y, Kimura H, Kuroiwa Y, Hachiya NS, Kaneko K. Neurosci Lett 353 49-52 (2003)
  122. NGF monoclonal antibody DS002 alleviates chemotherapy-induced peripheral neuropathy in rats. Liang ZJ, Tan J, Tang L, Xie ZB, Chen GJ, Liu GJ, Yuan L, Wang KX, Ding HP, Qiu H, Wang Q, Wang GF, Chen YL, Wang CH. Acta Pharmacol Sin 43 2841-2847 (2022)
  123. RC3/neurogranin negatively regulates extracellular signal-regulated kinase pathway through its interaction with Ras. Ryoo K, Hwang SG, Kim KJ, Choi EJ. Mol Cell Biochem 402 33-40 (2015)
  124. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Novel Recombination Human Nerve Growth Factor in Healthy Chinese Subjects. Shen Q, Zhang M, Jin Y, Di X, Liu R, Wang Z. CNS Drugs 37 231-242 (2023)
  125. The RNA-Binding Protein HuR Is Integral to the Function of Nociceptors in Mice and Humans. Kunder N, de la Peña JB, Lou TF, Chase R, Suresh P, Lawson J, Shukla T, Black B, Campbell ZT. J Neurosci 42 9129-9141 (2022)


Quick links